Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KYMR OTCMKTS:OXBDF NASDAQ:RARE NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$43.48$43.33$19.44▼$53.27$3.11B2.17616,664 shs647,042 shsOXBDFOxford BioMedica$7.35$6.09$3.15▼$7.35$778.82M1.1638 shsN/ARAREUltragenyx Pharmaceutical$31.29-0.7%$30.04$25.81▼$60.37$3.04B0.211.27 million shs1.91 million shsTLXTelix Pharmaceuticals$9.69+4.3%$12.81$8.93▼$30.36$3.14BN/A242,729 shs299,670 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics0.00%+0.42%+15.39%-8.06%-7.25%OXBDFOxford BioMedica0.00%0.00%+16.67%+57.73%+74.71%RAREUltragenyx Pharmaceutical-0.67%-0.82%+14.24%-20.36%-43.84%TLXTelix Pharmaceuticals+4.31%+3.53%-11.02%-44.50%+968,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKYMRKymera Therapeutics$43.48$43.33$19.44▼$53.27$3.11B2.17616,664 shs647,042 shsOXBDFOxford BioMedica$7.35$6.09$3.15▼$7.35$778.82M1.1638 shsN/ARAREUltragenyx Pharmaceutical$31.29-0.7%$30.04$25.81▼$60.37$3.04B0.211.27 million shs1.91 million shsTLXTelix Pharmaceuticals$9.69+4.3%$12.81$8.93▼$30.36$3.14BN/A242,729 shs299,670 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKYMRKymera Therapeutics0.00%+0.42%+15.39%-8.06%-7.25%OXBDFOxford BioMedica0.00%0.00%+16.67%+57.73%+74.71%RAREUltragenyx Pharmaceutical-0.67%-0.82%+14.24%-20.36%-43.84%TLXTelix Pharmaceuticals+4.31%+3.53%-11.02%-44.50%+968,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKYMRKymera Therapeutics 3.06Buy$58.7635.15% UpsideOXBDFOxford BioMedica 0.00N/AN/AN/ARAREUltragenyx Pharmaceutical 2.92Moderate Buy$81.50160.47% UpsideTLXTelix Pharmaceuticals 2.80Moderate Buy$21.33120.16% UpsideCurrent Analyst Ratings BreakdownLatest OXBDF, KYMR, RARE, and TLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025TLXTelix PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$23.00 ➝ $20.009/9/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.009/5/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$105.008/28/2025TLXTelix PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral8/28/2025TLXTelix PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.008/8/2025RAREUltragenyx PharmaceuticalCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$136.00 ➝ $128.008/6/2025RAREUltragenyx PharmaceuticalCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$112.00 ➝ $105.007/30/2025KYMRKymera TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$60.007/28/2025RAREUltragenyx PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy$80.007/15/2025KYMRKymera TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/14/2025RAREUltragenyx PharmaceuticalWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $34.00(Data available from 9/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKYMRKymera Therapeutics$47.07M66.05N/AN/A$12.90 per share3.37OXBDFOxford BioMedica$111.34M6.99N/AN/A$1.01 per share7.28RAREUltragenyx Pharmaceutical$560.23M5.38N/AN/A$2.76 per share11.34TLXTelix Pharmaceuticals$516.72M6.35$0.12 per share81.35$1.12 per share8.65Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKYMRKymera Therapeutics-$223.86M-$3.47N/AN/AN/A-616.03%-31.60%-27.12%10/30/2025 (Estimated)OXBDFOxford BioMedica-$195.90MN/A0.00N/AN/AN/AN/AN/AN/ARAREUltragenyx Pharmaceutical-$569.18M-$5.53N/AN/AN/A-87.34%-237.48%-37.66%11/4/2025 (Estimated)TLXTelix Pharmaceuticals$32.93MN/A0.0020.19N/AN/AN/AN/AN/ALatest OXBDF, KYMR, RARE, and TLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025KYMRKymera Therapeutics-$0.83-$0.95-$0.12-$0.95$17.37 million$11.48 million8/5/2025Q2 2025RAREUltragenyx Pharmaceutical-$1.27-$1.17+$0.10-$1.17$161.37 million$166.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKYMRKymera TherapeuticsN/AN/AN/AN/AN/AOXBDFOxford BioMedicaN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKYMRKymera TherapeuticsN/A8.328.32OXBDFOxford BioMedicaN/AN/AN/ARAREUltragenyx PharmaceuticalN/A2.452.30TLXTelix Pharmaceuticals0.992.782.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKYMRKymera TherapeuticsN/AOXBDFOxford BioMedicaN/ARAREUltragenyx Pharmaceutical97.67%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipKYMRKymera Therapeutics16.01%OXBDFOxford BioMedicaN/ARAREUltragenyx Pharmaceutical5.50%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKYMRKymera Therapeutics17071.50 million60.05 millionOptionableOXBDFOxford BioMedica891105.96 millionN/ANot OptionableRAREUltragenyx Pharmaceutical1,29496.37 million91.07 millionOptionableTLXTelix PharmaceuticalsN/A338.40 millionN/AN/AOXBDF, KYMR, RARE, and TLX HeadlinesRecent News About These CompaniesTelix Pharmaceuticals (NASDAQ:TLX) Price Target Cut to $20.00 by Analysts at HC Wainwright4 hours ago | americanbankingnews.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 10 at 2:02 PM | prnewswire.comTelix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer DiagnosisSeptember 9 at 7:00 PM | globenewswire.comTLX Investor News: If You Have Suffered Losses in Telix Pharmaceuticals Ltd. (NASDAQ: TLX), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 7, 2025 | globenewswire.comRosen Law Firm Encourages Telix Pharmaceuticals Ltd. Investors to Inquire About Securities Class Action Investigation - TLXSeptember 5, 2025 | prnewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Sets New 12-Month Low - What's Next?September 5, 2025 | marketbeat.comTelix Pharmaceuticals (ASX:TLX) Hits New Low Amid FDA ScrutinySeptember 5, 2025 | thebull.com.auTTelix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - What's Next?September 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLXSeptember 3, 2025 | prnewswire.comTelix Pharmaceuticals (ASX:TLX) Falls 24% in a Week After FDA Complete Response LetterSeptember 2, 2025 | finance.yahoo.comFY2026 Earnings Forecast for TLX Issued By William BlairSeptember 2, 2025 | marketbeat.comResearch Analysts Set Expectations for TLX FY2026 EarningsSeptember 2, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's WhyAugust 31, 2025 | marketbeat.comWilliam Blair Has Bearish Estimate for TLX FY2027 EarningsAugust 31, 2025 | marketbeat.comWedbush Analysts Decrease Earnings Estimates for TLXAugust 31, 2025 | marketbeat.comWilliam Blair Has Pessimistic View of TLX FY2027 EarningsAugust 31, 2025 | americanbankingnews.comFY2025 EPS Estimate for Telix Pharmaceuticals Cut by AnalystAugust 31, 2025 | americanbankingnews.comTelix Pharmaceuticals (NASDAQ:TLX) Reaches New 12-Month Low - Here's What HappenedAugust 30, 2025 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) Earns "Outperform" Rating from WedbushAugust 30, 2025 | marketbeat.comTelix Pharmaceuticals Limited (TLX) Hits Another Roadblock After SEC Subpoena, Shares Fall Again -- Hagens BermanAugust 29, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLXAugust 29, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 2025MP Materials: How One Move Redefined the U.S. Magnet Supply ChainBy Jeffrey Neal Johnson | August 27, 2025Amazon Faces Rare Downgrade—Is the Rally at Risk?By Sam Quirke | September 2, 2025Energy Fuels: Is This America's Most Strategic Stock?By Jeffrey Neal Johnson | September 6, 2025MP Materials Stock Rides Rare Earth Boom to New HighsBy Gabriel Osorio-Mazilli | August 12, 2025OXBDF, KYMR, RARE, and TLX Company DescriptionsKymera Therapeutics NASDAQ:KYMR$43.48 0.00 (0.00%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$44.26 +0.78 (+1.79%) As of 06:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Oxford BioMedica OTCMKTS:OXBDF$7.35 0.00 (0.00%) As of 09/9/2025Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Ultragenyx Pharmaceutical NASDAQ:RARE$31.29 -0.21 (-0.67%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$32.28 +0.99 (+3.18%) As of 05:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.Telix Pharmaceuticals NASDAQ:TLX$9.69 +0.40 (+4.31%) Closing price 09/10/2025 04:00 PM EasternExtended Trading$9.45 -0.24 (-2.48%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle Has Spoken: AI Changes Everything Despite Pullback, Rocket Lab Still Looks Primed for a Breakout Part of the Club: Robinhood & AppLovin Soar on S&P 500 Inclusion Analyst Upgrades Strengthen Microsoft’s Long-Term Outlook Celsius Stock Surges After Blowout Earnings and Pepsi Deal Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Alphabet Stock’s Weakness Was Wall Street’s Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
